Léčba nemalobuněčného plicního karcinomu gefitinibem
| Title in English | Gefitinib in treatment of non-small-cell-lung cancer |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Field | Pneumology |
| Keywords | gefitinib; biological treatment; non-small-cell-lung-cancer; epidermal factor growth receptor |
| Attached files | |
| Description | Lung carcinoma is the most common cause of death among cancer patients. Non-small-cell-lung cancer is the most frequent histologi-cal type of lung carcinoma. Gefitinib is intended for biological treatment of locally advanced or metastatic non-small-cell-lung cancer in patients with activation mutation of epidermal factor growth receptor, in first line of treatment, without previous chemothrapy. Case study discusses two patients treated with gef itinib, with similar initial parameters, but diferent outcomes of the treatment. |